Table 2.

Predicted temozolomide tissue AUC values for the considered dosing and schedule protocols

AUC6 h (μg/mL·h)AUC12 h (μg/mL·h)AUC24 h (μg/mL·h)
Protocol A
    Brain tumor12.5017.5718.91
    Normal brain7.7911.8012.86
Protocol B
    Brain tumor26.8237.3840.37
    Normal brain16.8125.1227.47
Protocol C
    Brain tumor13.6718.6219.92
    Normal brain8.6612.5313.55
  • NOTE: Protocol A: single oral dose of 100 mg/m2/d daily for 5 consecutive days every 28 d. Protocol B: single oral dose of 200 mg/m2/d daily for 5 consecutive days every 28 d. Protocol C: continuous oral schedule of 75 mg/m2/d daily for 7 wk.

    The AUC values have been derived integrating the predicted tissue concentration-time curve from 0 to 6 h (AUC6 h), from 0 to 12 h (AUC12 h), and from 0 to 24 h (AUC24 h). The predicted tissue concentration was obtained by convolution analysis using the average human PET-derived IRF and the nonradioactive plasma temozolomide concentration in different dosing protocols, using Eq. B.